Unknown

Dataset Information

0

A collagen-binding EGFR antibody fragment targeting tumors with a collagen-rich extracellular matrix.


ABSTRACT: Many tumors over-express collagen, which constitutes the physical scaffold of tumor microenvironment. Collagen has been considered to be a target for cancer therapy. The collagen-binding domain (CBD) is a short peptide, which could bind to collagen and achieve the sustained release of CBD-fused proteins in collagen scaffold. Here, a collagen-binding EGFR antibody fragment was designed and expressed for targeting the collagen-rich extracellular matrix in tumors. The antibody fragment (Fab) of cetuximab was fused with CBD (CBD-Fab) and expressed in Pichia pastoris. CBD-Fab maintained antigen binding and anti-tumor activity of cetuximab and obtained a collagen-binding ability in vitro. The results also showed CBD-Fab was mainly enriched in tumors and had longer retention time in tumors in A431 s.c. xenografts. Furthermore, CBD-Fab showed a similar therapeutic efficacy as cetuximab in A431 xenografts. Although CBD-Fab hasn't showed better therapeutic effects than cetuximab, its smaller molecular and special target may be applicable as antibody-drug conjugates (ADC) or immunotoxins.

SUBMITTER: Liang H 

PROVIDER: S-EPMC4756367 | biostudies-other | 2016 Feb

REPOSITORIES: biostudies-other

Similar Datasets

| S-EPMC10721602 | biostudies-literature
| S-EPMC5274546 | biostudies-literature
| S-EPMC5573064 | biostudies-literature
| S-EPMC10965421 | biostudies-literature
| S-EPMC6342449 | biostudies-literature
| S-EPMC6544883 | biostudies-literature
| S-EPMC5120351 | biostudies-literature
| S-EPMC7556022 | biostudies-literature
| S-EPMC1152369 | biostudies-other
| S-EPMC6993244 | biostudies-literature